AstraZeneca: successful trial in polyneuropathy
(CercleFinance.com) - This morning AstraZeneca has announced that results from a Phase III trial have showed that eplontersen met its primary endpoints for 66 weeks in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
The results were consistent with the positive results at 35 weeks announced in June 2022, the lab said.
Sami Khella, Chief, Department of Neurology, Penn Presbyterian Medical Center and Professor of Clinical Neurology, University of Pennsylvania School of Medicine, said, “The positive results from the 66-week analysis of the Phase III NEURO-TTRansform trial show that eplontersen provided consistent and sustained transthyretin protein reduction and that a substantial number of patients improved in measures of both neuropathy progression and quality of life".
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The results were consistent with the positive results at 35 weeks announced in June 2022, the lab said.
Sami Khella, Chief, Department of Neurology, Penn Presbyterian Medical Center and Professor of Clinical Neurology, University of Pennsylvania School of Medicine, said, “The positive results from the 66-week analysis of the Phase III NEURO-TTRansform trial show that eplontersen provided consistent and sustained transthyretin protein reduction and that a substantial number of patients improved in measures of both neuropathy progression and quality of life".
Copyright (c) 2023 CercleFinance.com. All rights reserved.